Colchicines-induced neurotoxicity as an animal model of sporadic dementia of Alzheimer's type

Pharmacological Reports

Volumn 59, Issue 3, 2007, Pages 274-283

  Kumar, Anil ^a   Seghal, Neha ^a   Naidu, Pattipati S ^a   Padi, Satyanaryana S V ^a   Goyal, Richa ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Alzheimer's disease; Colchicine; Neurotoxicity; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; COLCHICINE; FREE RADICAL; GLUTATHIONE; LIPID; NITRITE; RIVASTIGMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CELL DAMAGE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOSKELETON; DEMENTIA; DISEASE MODEL; DRUG SCREENING; EXPERIMENTAL MODEL; LIPID PEROXIDATION; MALE; MAZE TEST; MEMORY DISORDER; NERVE CELL LESION; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; SENILE PLAQUE; TASK PERFORMANCE;

EID: 34548142159     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Auld DS, Kar S, Quirion R: β-Amyloid peptides as direct cholinergic neuromodulators: missing link. Trends Neurosci, 1998, 58, 408-417.
2. Bartus RT, Dean RL, Poontecarvo MJ, Flicker C: The cholinergie hypothesis: historical overview, current, perspective and future perspective. Ann NY Acad Sci, 1985, 444, 332-358.
3. Bartus RT, Dean RL, Beer B, Lippa AS: The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-417.
4. Bazan NG: Neuroprotective signaling in neurodegeneration and neurorepair. Pharmacol Rep, 2005, 57, 405-411.
5. Beal MF: Aging, energy, and oxidative stress in neurodegenerative disease. Ann Neurol, 1995, 38, 357-366.
6. Bejar C, Wang RH, Weinstock M: Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol, 1999, 383, 231-240.
7. Bensimon G, Chermat R: Microtubule disruption and cognitive deficits: effects of colchicine on learning behavior in rats. Pharmacol Biochem Behav, 1993, 44, 491-494.
8. Blokland A, Hinz VC, Schmidt BH: Effects of metrifonate and tacrine in the spatial Morris task and modified Irwin test: evaluation of the efficacy/safety profile in rats. Drug Dev Res, 1995, 36, 166-179.
9. Bondy CS: The relation of oxidative stress and hyperexcitation to neurological disease. Proc Soc Exp Biol Med, 1995, 208, 337-345.
10. Cheng DH, Ren H, Tang XC, Huperzine A: A novel promishig acetylcholinesterase inhibitors. Neuroreport, 1996, 8, 97-101.
11. Conner JM, Fass-Holmes B, Varon S: Changes in nerve growth factor immunoreactivity following entorhinal cortex lesions: possible molecular mechanism regulating cholinergic sprouting. J Comp Neurol, 1994, 345, 409-418.
12. Dasheiff RM, Ramirez LF: The effects of colchicine in mammalian brain from rodents to Rhesus monkeys. Brain Res Rev, 1985, 10, 47-67.
13. Dwaine EE, Thomas JW: Cholinergic cell loss and cognitive impairments following intracerebroventricular or intradentate injection of colchicines. Brain Res, 1990, 17, 157-167.
14. Ellman GL, Courtney KD, Andres V, Featherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol, 1961, 7, 88-95.
15. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys, 1959, 82, 70-74.
16. Emerich DF, Walsh TJ: Cholinergic loss and cognitive impairment following intraventricular or intradentate injections of colchicines. Brain Res, 1990, 517, 57-167.
17. Flaherty CF, Rowan GA, Emerich DF, Walsh TJ: Effects of intrahippocampal administration of colchicine on incentive contrast and on radial maze performance. Behav Neurosci, 1989, 103, 319-328.
18. Frautschy SA, Hu W, Kim P, Miller SA, White-Harris ME, Chu T, Cole G M: Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol Aging, 2001, 22, 993-1005.
19. Gornall AG, Bardawill CT, David MM: Determination of serum protein by means of the Biuret reaction. J Biol Chem, 1949, 177, 751-766.
20. 15N] nitrate in biological fluids. Ann Biochem, 1982, 126, 131-138.
21. Greig NH, Lahiri DK, Sambamurti K: Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Inter Psychogeriatric Assoc, 2002, 14, 77-91.
22. Grutzendler J, Morris JC: Cholinesterase inhibitors for Alzheimer's disease. Drugs, 2001, 61, 41-52.
23. Hanson M, Estrom A: Mitosis inhibitors and axonal transport. Int Rev Cytol, 1978, 7, 373-402.
24. Iqbal K, Grunde-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, Wisnieski HM: Defective Brain Microtubule assembly in Alzheimer's disease. Lancet, 1986, 11, 421-426.
25. 3 antagonist ondansetron and H(3) antagonist thioperamide in models of cognition and cholinergic function. Behav Pharmacol, 1996, 7, 513-525.
26. Kumar A, Seghal N, Padi SV, Naidu PS: Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats. Eur J Pharmacology, 2006, 551, 58-66.
27. Kumar V, Gupta YK: Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol Biochem Behav, 2002, 73, 565-571.
28. Markesbery WR: Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med, 1999, 23, 134-147.
29. McClure WO: Effects of drugs upon axoplasmic transport. Adv Pharmacol Chemother, 1972, 10, 185-220.
30. McDonald MP, Overmier JB: Present imperfect: a critical review of animal models of the mnemonic impairments in Alzheimer's disease. Neurosci Biobehav Rev, 1998, 22, 99-120.
31. McIlroy S, Craig D: Neurobiology and genetics of behavioral syndromes of Alzheimer's disease. Curr Alzheimer Res, 2004, 1, 135-142.
32. Nabeshima T: Behavioral aspects of cholinergic transmission, role of basal forebrain cholinergic system in learning and memory. Prog Brain Res, 1993, 98, 405-441.
33. Nakagawa YS, Nakamura S, Kase Y, Noguchi T, Ishihara T: Colchicine lesions in the rat hippocampus mimic the alterations of several markers in Alzheimer's disease. Brain Res, 1987, 408, 57-64.
34. Nakayama T, Sawada T: Involvement of microtubule integrity in memory impairment caused by colchicines. Pharmacol Biochem Behav, 2002, 71, 119-138.
35. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drugs Saf, 1998, 19, 465-480.
36. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y: Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol, 2000, 22, 89-95.
37. Perry EK, Tomlinson BE, Blessed G, Bergmenn PH, Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J, 1978, 2, 1457-1459.
38. Prickaerts SJ, Honig, W, Schmidt BH, Blokland A: Metrifonate improves working but not reference memory performance in a spatial cone field task. Eur J Pharmacol, 1999, 380, 61-65.
39. Richardson J, Burns A, Dennis K: Mouse models of Alzheimer's disease: a quest for plaques and tangles. ILAR J, 2002, 43, 89-99.
40. Riekkinen P, Schmidt B, Stefanski R, Kuitunen J, Riekkinen M: Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated medial septum-lesioned and aged rats. Eur J Pharmacol, 1996, 309, 121-130.
41. Scali G, Giovannini MG, Bartolini L, Propsperi C, Hinz V, Schmidt B: Effect of metrifonate on extracellular brain acetylcholine and object recognition in rats. Eur J Pharmacol, 1997, 325, 173-180.
42. Spires TL, Hyman BT: Transgenic models of Alzheimer's disease: Learning from animals. NeuroRx, 2005, 2, 423-437.
43. Steward O, Goldschmidt RB, Sutula T: Neurotoxicity of colchicine and other tubulin-binding agents: a selective vulnerability of certain neurons to the disruption of microtubules. Life Sci, 1984, 35, 43-51.
44. Tilson HA, Rogers BC, Grimes L, Harry GJ, Peterson NJ, Hong JS, Dyer RS: Time-dependent neurobiological effects of colchicine administered directly into the hippocampus of rats. Brain Res, 1987, 408, 163-172.
45. Tilson HA, McLamb RL, Shaw S, Rogers BC, Pediaditakis P, Cook L: Radial arm maze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents. Brain Res, 1988, 438, 83-94.
46. Tilson HA, Peterson N: Colchicine as an investigative tool in neurobiology. Toxicology, 1987, 46, 159-173.
47. Verma A, Kulkarni SK: Evaluation of learning and memory mechanisms employing plus maze in rats and mice. Prog Neuropsychopharmacol Biol Psychiatry, 1992, 16, 117-125.
48. Walsh TJ, Schulz DW, Tilson HA, Schmechel DE: Colchicine induced granule cell loss in rat hippocampus: selective behavioral and histological alterations. Brain Res, 1986, 398, 23-36.
49. Wang RH, Bejar C, Weinstock M: Gender differences in the effect of rivastigmine on brain cholinestrase activity and cognitive function in rats. Neuropharmacology, 2000, 39, 497-506.
50. Szutowicz A, Bielarczyk H, Gul S: Phenotype-dependent vulnerability of cholinergic neurons to neurodegenerative signals. Pharmacol Rep, 2005, 57, 429-430.
51. Wilcock GK, Esiri MM, Bowen DM, Smith CCT: Alzheimer's disease: correlation of cortical choline acetyl transference activity with severity of dementia and histological abnormalities. J Neurol Sci, 1982, 57, 407-417.
52. Wills E D: Mechanism of lipid peroxide formation in animal tissues. Biochem J, 1966, 99, 667-676.
53. Wilson L, Friedkin M: The biochemical events of microtubule synthesis and properties of colchicine labeled with tritium in its acetyl moiety. Biochemistry, 1966, 51, 2463-2468.